Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners.

OsoBio is a contract manufacturer of highly complex injectable drug products; its experience in large-scale commercial production is highly complementary to AMRI's early stage drug product manufacturing capabilities.

Total consideration paid was $110 million. AMRI financed the transaction with cash on hand.